title: Influence of sucralfate on trilisate bioavailability.
abstract: Twelve healthy human volunteers were randomized to receive either choline-magnesium trisalicylate (CMT) 1.5 g orally every 12 hours or a combination of CMT plus sucralfate 1 g orally every 6 hours for 5 days before the blood sampling day. After a 3-week washout period, the subjects were crossed over to receive the alternate treatment for 5 days. The mean (+/- SD) area under the curve was 2668 (729) mg - hr/L and 2748 (716) mg - hr/L for CMT and CMT/sucralfate treatments, respectively. Mean (+/- SD) maximum concentration was 275 (69) mg/L and 283 (75) mg/L for CMT and CMT/sucralfate administrations, respectively. Mean (+/- SD) time to maximum concentration for CMT and CMT/sucralfate treatments was 1.8 (0.6) hours and 1.7 (0.7) hours, respectively. There were no significant differences detected for any parameter, therefore sucralfate does not affect rate or extent of CMT absorption.
authors.affiliation: Department of Pharmacy, Hartford Hospital, CT 06115.
authors.forename: D K
authors.initials: DK
authors.lastname: Schneider
authors.forename: R H
authors.initials: RH
authors.lastname: Gannon
authors.forename: K R
authors.initials: KR
authors.lastname: Sweeney
authors.forename: P A
authors.initials: PA
authors.lastname: DeFusco
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D002794:Choline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D012459:Salicylates / Q000008:administration & dosage / Q000493:pharmacokinetics*; D013392:Sucralfate / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D012459:Salicylates; D013392:Sucralfate; C017959:choline magnesium trisalicylate; D002794:Choline